Peter Tsvetkov, Ph.D.
Affiliations: | 2010 | Weizmann Institute of Science, Rehovot, Israel |
Area:
Physiology Biology, Oncology, AgingGoogle:
"Peter Tsvetkov"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Yosef Shaul | grad student | 2010 | Weizmann Institute | |
| (Regulation of Protein Degradation by Default.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dreishpoon MB, Bick NR, Petrova B, et al. (2023) FDX1 regulates cellular protein lipoylation through direct binding to LIAS. The Journal of Biological Chemistry. 105046 |
| Dreishpoon MB, Bick NR, Petrova B, et al. (2023) FDX1 regulates cellular protein lipoylation through direct binding to LIAS. Biorxiv : the Preprint Server For Biology |
| Tsvetkov P, Adler J, Strobelt R, et al. (2021) NQO1 Binds and Supports SIRT1 Function. Frontiers in Pharmacology. 12: 671929 |
| Tsvetkov P, Myers N, Adler J, et al. (2020) Degradation of Intrinsically Disordered Proteins by the NADH 26S Proteasome. Biomolecules. 10 |
| Tsvetkov P, Eisen TJ, Heinrich SU, et al. (2020) Persistent Activation of mRNA Translation by Transient Hsp90 Inhibition. Cell Reports. 32: 108001 |
| Graindorge A, Pinheiro I, Nawrocka A, et al. (2020) Author Correction: In-cell identification and measurement of RNA-protein interactions. Nature Communications. 11: 3498 |
| Tsvetkov P, Detappe A, Cai K, et al. (2019) Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nature Chemical Biology |
| Tsvetkov P, Adler J, Myers N, et al. (2018) Oncogenic addiction to high 26S proteasome level. Cell Death & Disease. 9: 773 |
| Newby GA, Kiriakov S, Hallacli E, et al. (2017) A Genetic Tool to Track Protein Aggregates and Control Prion Inheritance. Cell |
| Tsvetkov P, Sokol E, Jin D, et al. (2017) Abstract A28: Targeting the epigenetic state regulating cancer cell vulnerability to proteasome inhibition Clinical Cancer Research. 23 |